Coriolis Pharma US Inc. Launches Operations in North Carolina

Coriolis Pharma US Inc. Launches Operations in North Carolina

Strengthening Global Presence with Advanced Analytical Capabilities for Biopharmaceutical Innovation

Durham, NC, USA – March 11, 2026 – Coriolis Pharma today celebrates the grand opening of its new U.S. headquarter and laboratory, marking the start of operations at the Alexandria Center for Advanced Technologies (ACAT) in North Carolina’s Research Triangle Park (RTP). This expansion enables Coriolis to provide its North American clients with direct access to specialized expertise in formulation and drug product development as well as analytical characterization of biopharmaceutical products.

The new site offers three core services:

• Particle Analysis and Fast Track Analytics – High precision identification and characterization of particles and ad hoc non-GMP analytical services
• Formulation Development – Preclinical, early and late-stage formulation development for liquid, and frozen-liquid products
• Drug Product Development – Primary packaging material selection studies and in-depth drug product and filling process characterization work to support IND/BLA filings

The services will be rolled out progressively throughout 2026, with all capabilities available by Q4 2026. Certain fast-track analytical services are starting with actual projects in March 2026. In addition, all Coriolis services will be available through close collaboration with experts at the German headquarters and their global partners, providing clients with comprehensive end-to-end solutions from a single point of contact.

“Opening our lab and US Headquarter in North Carolina is a major leap forward for Coriolis. It fuels our mission to empower innovation where it happens,” said Silvia Steyrer‑Gruber, CEO of Coriolis Pharma. “The region’s scientific excellence, cutting‑edge biotech and manufacturing ecosystem and collaborative energy make it the perfect home for our next chapter.”

“We are excited to bring our deep scientific expertise and comprehensive service offerings to the vibrant life science community in North Carolina,” added John Gabrielson, President of Coriolis Pharma US Inc. “Together with our colleagues in Germany and partners worldwide, we will deliver solutions that meet the highest quality standards – empowering companies in the U.S. to accelerate their development programs and drive innovation forward.”

This milestone positions Coriolis to spark new scientific momentum—enabling breakthroughs that shape the future of biopharmaceutical innovation. It marks a meaningful step in strengthening the company’s ability to support discoveries that ultimately benefit patients around the world.

End of Press Release